- More than a dozen health information exchanges, service providers join Surescripts
- Keryx Biopharmaceuticals announces NDA for hyperphosphatemia treatment in chronic kidney disease patients
- Study: Limiting NPs' scope of practice leads to higher costs
- Senate passes Drug Quality and Security Act
- Walgreens partners with United Nations Foundation's Shot@Life campaign
NEW YORK Keryx has begun its phase-3 clinicial trial of a drug designed to treat elevated serum phosphorous levels in patients with end-stage renal disease on dialysis.
The drug maker said that the Zerenex trial will include two clinical studies, examining approximately 300 ESRD patients on hemodialysis or peritoneal dialysis over a 52-week safety assessment period for a long-term efficacy study -- as well as 150 ESRD patients on hemodialysis or peritoneal dialysis over a 52-week safety assessment period for a short-term efficacy study -- to determine whether the investigational drug will treat elevated serum phosphorous levels, also known as hyperphosphatemia.
Patient enrollment is expected to take approximately six to nine months.